Home › NDC Lookup › Ingredients › Insulin Human › 47918-0904-30
Afrezza Insulin Human Kit — NDC 47918-0904-30 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 47918-0904-30: Afrezza Insulin Human Kit

by Mannkind Corporation · 1 KIT in 1 CARTON * 15 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE * 15 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE

This is a package of Afrezza Insulin Human Kit from Mannkind Corporation, first listed with the FDA Jun 2025 and currently FDA-listed. It is this product's only package size.

🏷️ FDA NDC (as labeled) 47918-904-30 billing pads the product segment with a zero
Rx only Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 47918-904-30 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
47918 labeler · 904 product · 30 package
Package marketed since
Jun 1, 2025
Sample package
Yes — professional sample, not for sale
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 4791890430 4
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Insulin Human (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 6, 2026 — CGMP Deviations (Baxter Healthcare Corporation) · FDA recall D-0806-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 47918-904-30
Product NDC 47918-904
11-digit billing NDC 47918090430
UNII 1Y17CTI5SR
Application # BLA022472
SPL Set ID 29f4637b-e204-425b-b89c-7238008d8c10
Established class (EPC) Insulin
Chemical class Insulin
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2025-06-01
Route RESPIRATORY (INHALATION)
Dosage form KIT
Biologic (Purple Book) 351(a)
Quick answers
  • RxCUI (RxNorm): 1543202
Why two NDCs? The FDA registers this code as 47918-904-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 47918-0904-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Insulin class.

Pharmacologic class Insulin
Drug family (ATC) Insulins and analogues for injection, fast-acting, Insulins and analogues for injection, intermediate-acting, Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Insulin inhalation is to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) and type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Insulin inhalation is a short-acting, man-made version of human insulin. Insulin inhalation works by replacing the insulin that is normally produced by the body and by helping to move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from pro...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Because Afrezza is inhaled directly into the lungs, it can cause sudden, dangerous airway tightening — especially in people who already have lung conditions like asthma or COPD. Th...
  • Why do I have to get a lung test before I can use Afrezza?
  • Yes, coughing is actually the most common side effect of Afrezza — about 1 in 4 adults report it. For most people it's mild and manageable, though it is the most common reason peop...
  • I keep coughing every time I use Afrezza — is that normal, and will it go away?
📖 Read our full Insulin Human Inhalation guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
47918-0904-30 You're viewing this Main listing 1 KIT in 1 CARTON * 15 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE * 15 CARTRIDGE in 1 BLISTER PACK / 1 POWDER, METERED in 1 CARTRIDGE Sample 2025-06-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Afrezza 47918-0880-18 Mannkind 1 kit $7.793 — Availability likely —
Afrezza 47918-0902-18 Mannkind 1 kit $10.323 — Availability likely —
Afrezza 47918-0898-18 Mannkind 1 kit $13.038 — Availability likely —
Afrezzathis 47918-0904-30 Mannkind 1 kit — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
2014
First FDA approval
Jun 2014
📍
2026
Currently FDA-listed
12 years listed
🔓
·
Biosimilar pathway open
listed protections lapsed 2026
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

🛡️ Latest patent/protection date listed: The latest listed FDA patent/protection lapsed Jun 2026 — those protections no longer apply, though a biosimilar still needs FDA licensure and a manufacturer to market it.
📅 FDA approved Jun 27, 2014

Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.

FDA Purple Book — biosimilars & interchangeables ⓘ
🔒 No FDA-licensed biosimilars or interchangeable biosimilars are listed yet for this biologic. It currently has no biosimilar competition in the FDA Purple Book.
Source: FDA Purple Book (purplebooksearch.fda.gov), matched on the reference product’s active ingredient.
Patents & exclusivity — FDA Purple Book
Exclusivity RefProduct
2014 2016 2018 2020 2022 2024 2026
Today
LOE
Biologic patent Exclusivity
🏛️Reference-product exclusivity
A flat 12 years of FDA market protection from first licensure. No biosimilar can be licensed before it ends — regardless of patents.
🧪Listed biologic patents
Patents the reference maker lists covering the molecule, formulation, or manufacturing. A biosimilar generally can’t launch until these resolve.
🔁Interchangeability
An interchangeable biosimilar may be substituted at the pharmacy (state laws vary). The first one can earn its own exclusivity period.
🛈 What do these terms mean?
Biologic patent
A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
Reference-product exclusivity
A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
Interchangeable exclusivity
The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
Earliest biosimilar (LOE)
The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.

Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.

FDA exclusivity
CodeWhat it grantsExpires
RefProductReference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this dateJun 27, 2026
Common questions
Is there a biosimilar for this drug?
No FDA-licensed biosimilar is currently listed for this biologic in the FDA Purple Book.
Why do different websites show different biosimilar dates?
Biosimilar availability isn’t based on one single date. Some sources use the reference-product exclusivity, some use the last listed patent, and patent litigation, settlements, and licenses can all change the real-world launch date. This page shows the underlying Purple Book dates so you can see why estimates differ.
Can a biosimilar launch before the last patent expires?
Sometimes. A biosimilar maker may settle with the reference manufacturer or receive a license to launch earlier. In other cases, the last listed protection delays competition.
What does “current Purple Book estimate” mean?
It means we’re using the latest patent and exclusivity dates currently listed in the FDA Purple Book. It is not a guaranteed launch date.
What does “FDA listed” mean?
It means the product appears in the FDA’s official directory. That’s a good sign a product exists for the U.S. market, but on its own it does not confirm a pharmacy can get it today. Where we have recent retail pricing data, we label it “Availability likely” instead.
What does a patent or protection date mean here?
It’s the latest date currently listed in the FDA Purple Book for a patent or exclusivity on the reference biologic. It can affect when a biosimilar becomes widely available — but it is not a guaranteed launch date. Settlements and licenses can move the real date earlier or later.
Built from the FDA Purple Book Patent List (patents the reference-product sponsor has publicly listed under the BPCIA) plus reference-product exclusivity. Biosimilars cannot launch until these clear; patent litigation and settlements can shift the real date. Biologics have no small-molecule generics — competition comes from FDA-licensed biosimilars, not the Orange Book.
Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Insulin Human Inhalation inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

The FDA label contains product information, but this exact NDC could not be matched safely to one product block. We intentionally withheld sibling strengths’ ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMannkind Corporation
FDA applicationBLA022472 (BLA)
Labeler code47918
First marketedJun 2025
Product typeHuman Prescription Drug
Portfolio10 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 173 words ▾

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) [see Warnings and Precautions ( 5.1 )]. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD [see Contraindications ( 4 )]. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV 1 ) to identify potential lung disease in all patients [see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.1 )].

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE See full prescribing information for complete boxed warning. Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). ( 5.1 ) AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.

( 4 ) Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV 1 ) to identify potential lung disease in all patients. ( 2.1 ), ( 5.1 )

🎯 Indications and Usage 148 words ▾

1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warnings and Precautions ( 5.6 )] .

The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking [see Warnings and Precautions ( 5.5 )].

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION Only administer via oral inhalation using the AFREZZA inhaler ( 2.2 ) Administer at the beginning of each meal ( 2.2 ) See full prescribing information for the recommended starting mealtime dosage in insulin-naïve patients and patients who are using subcutaneous mealtime insulin, or pre-mixed insulin ( 2.3 ) Modify the mealtime AFREZZA dosage based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal ( 2.4 ) If blood glucose control is not achieved with increased AFREZZA dosages, consider discontinuing AFREZZA ( 2.4 )

2.1Lung Function Assessment Prior to Administration AFREZZA is contraindicated in patients with chronic lung disease because of the risk of acute bronchospasm in these patients. Before initiating AFREZZA, perform a medical history, physical examination and spirometry (FEV 1 ) in all patients to identify potential lung disease [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )].

2.2Important Administration Information Prior to initiation, train patients and/or their caregiver(s) on proper administration of AFREZZA. After training, adult and pediatric patients aged 10 and older may self-administer AFREZZA if the healthcare provider determines that it is appropriate. Refer patients to the Instructions for Use for detailed instructions and visuals on how to prepare, administer, and store AFREZZA; use the AFREZZA cartridges; and use the AFREZZA inhaler.

Only administer AFREZZA via oral inhalation using the AFREZZA Inhaler. Administer AFREZZA at the beginning of each meal. Administer AFREZZA using a single inhalation per cartridge (if the dose is greater than the contents of a single cartridge, more than one cartridge is needed) [see Dosage and Administration ( 2.3 ), Dosage Forms and Strengths ( 3 )].

To administer AFREZZA: Keep the inhaler level with the white mouthpiece on top and purple base on the bottom after a cartridge has been inserted into the inhaler. Loss of drug effect can occur if the inhaler is turned upside down, held with the mouthpiece pointing down, shaken, or dropped after the cartridge has been inserted but before the dose has been administered. If any of the above occur, replace the cartridge before use.

Hold the inhaler away from the mouth and fully exhale. After the inhaler is placed in the mouth and the lips form a seal, tilt the inhaler down towards the chin while keeping the head level. With the mouth closed around the mouthpiece, inhale deeply through the inhaler.

Hold the breath for as long as comfortable and at the same time remove the inhaler from the mouth. After holding the breath, exhale and continue to breathe normally. The AFREZZA Inhaler can be used for up to 15 days from the date of first use.

After 15 days of use, discard the inhaler and replace it with a new inhaler.

2.3Recommended Starting Mealtime Dosage of AFREZZA Insulin naïve patients The initial dosage of AFREZZA is 4 units inhaled at the beginning of each meal. Switching from Other Mealtime (prandial) Insulin Regimens to AFREZZA When switching from another insulin to AFREZZA, a different insulin dosage may be needed and increased frequency of blood glucose monitoring and monitoring for signs and symptoms of hypoglycemia may be needed [see Warnings and Precautions ( 5.2 , 5.3 ), Clinical Pharmacology ( 12.2 , 12.3 )]. Subcutaneous, Mealtime (prandial) Insulin: Follow the recommendations in Table 1 to convert each injected mealtime insulin dosage (or bolus dosage for patients using insulin pumps) to the recommended mealtime dosage of AFREZZA.

Subcutaneous, Pre-Mixed Insulin: Refer to the prescribing information for the pre-mixed insulin to estimate the mealtime subcutaneous insulin dosage based on the product’s pharmacokinetic and pharmacodynamic properties. Follow the recommendations in Table 1 to convert each estimated injected mealtime dosage to an AFREZZA mealtime dose. If basal insulin is clinically indicated, refer to the prescribing… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 51 words ▾

3 DOSAGE FORMS AND STRENGTHS Inhalation Powder: 3 single-use cartridges of insulin human as white powder labeled “afrezza”. Each AFREZZA inhalation cartridge delivers: 4 units (blue cartridge) 8 units (green cartridge) 12 units (yellow cartridge) Inhalation powder in single-use cartridges of: 4 units, 8 units, or 12 units ( 3 )

⛔ Contraindications 116 words ▾

4 CONTRAINDICATIONS AFREZZA is contraindicated: During episodes of hypoglycemia [see Warnings and Precautions ( 5.3 )]. In patients with chronic lung disease, such as asthma or COPD, because of the risk of acute bronchospasm [see Warnings and Precautions ( 5.1 )]. In patients with a previous severe hypersensitivity reaction to any regular human insulin product or any of the inactive ingredients in AFREZZA.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with AFREZZA [see Warnings and Precautions ( 5.7 )]. During episodes of hypoglycemia ( 4 ) Chronic lung disease, such as asthma, or COPD ( 4 ) Hypersensitivity to any regular human insulin product or any of the inactive ingredients in AFREZZA ( 4 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen : Make necessary changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed. ( 5.2 ) Hypoglycemia (may be life-threatening): Increase frequency of glucose monitoring in patients at higher risk for hypoglycemia and those who have reduced symptomatic awareness of hypoglycemia.

( 5.3 ) Decline in Pulmonary Function : Assess pulmonary function (e.g., spirometry (FEV 1 )) at baseline, after 6 months of therapy, and annually, even in the absence of pulmonary symptoms. In patients who have a decline of ≥ 20% in FEV 1 from baseline, consider discontinuing AFREZZA. Consider more frequent monitoring of pulmonary function in patients with pulmonary symptoms ( 5.4 ) Lung Cancer : In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.

( 5.5 ) Diabetic Ketoacidosis : In patients at risk for DKA, increase the frequency of glucose monitoring and consider changing to alternate route of insulin delivery. ( 5.6 ) Hypersensitivity Reactions : Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with AFREZZA. If hypersensitivity reactions occur, discontinue AFREZZA, treat per standard of care and monitor until symptoms and signs resolve.

( 5.7 ) Hypokalemia (may be life-threatening): Monitor potassium levels in patients at risk of hypokalemia. ( 5.8 ) Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists: Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs. ( 5.9 )

5.1Acute Bronchospasm in Patients with Chronic Lung Disease Because of the risk of acute bronchospasm, AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD [see Contraindications ( 4 )] . Before initiating therapy with AFREZZA, evaluate patients with a medical history, physical examination, and spirometry (FEV 1 ) to identify potential underlying lung disease. Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and COPD.

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. In this study, a mean decline in FEV 1 of 400 mL was observed 15 minutes after a single AFREZZA dose in patients with asthma. In a subset study of 8 patients with COPD, a mean decline in FEV 1 of 200 mL was observed 18 minutes after a single AFREZZA dose.

5.2Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen Changes in an insulin regimen (e.g., insulin strength, manufacturer, injection site or type, or method of administration) may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions ( 5.3 )] or hyperglycemia. If clinically indicated, make any necessary changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. For patients with type 2 diabetes mellitus, dosage modifications of concomitant oral antidiabetic treatment may be needed [see Drug Interactions ( 7 )] .

5.3Hypoglycemia Hypoglycemia is the most common adverse reaction associated with insulins, including AFREZZA. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).

AFREZZA's time action profile impacts the timing of hypoglycemia following inhalation of th… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Acute bronchospasm in patients with chronic lung disease [see Warnings and Precautions ( 5.1 )] Hypoglycemia [see Warnings and Precautions ( 5.3 )] Decline in pulmonary function [see Warnings and Precautions ( 5.4 )] Lung cancer [see Warnings and Precautions ( 5.5 )] Diabetic ketoacidosis [see Warnings and Precautions ( 5.6 )] Hypersensitivity reactions [see Warnings and Precautions ( 5.7 )] The most common adverse reactions associated with AFREZZA (2% or greater incidence) are hypoglycemia, cough, and throat pain or irritation ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact MannKind at 1-877-323-8505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Clinical Trials in Adults with Type 1 or Type 2 Diabetes Mellitus The data described below reflect exposure of 3,017 adult patients to AFREZZA and include 1,026 patients with type 1 diabetes mellitus and 1,991 patients with type 2 diabetes mellitus.

The mean exposure duration was 8.2 months for patients with type 1 diabetes mellitus and those with type 2 diabetes mellitus [see Clinical Studies ( 14.2 , 14.3 )] . In the overall population: 1,874 patients with type 1 or type 2 diabetes mellitus were exposed to AFREZZA for 6 months and 724 patients for greater than one year. 620 and 1,254 patients with type 1 or type 2 diabetes mellitus, respectively, were exposed to AFREZZA for up to 6 months.

238 and 486 patients with type 1 or type 2 diabetes mellitus, respectively, were exposed to AFREZZA for greater than one year (median exposure was 1.8 years). AFREZZA was studied in placebo and active-controlled adult trials (n = 3 and n = 10, respectively). The mean age of the adult population was 50 years and 20 patients were older than 75 years of age; 51% of the population were males; 83% were White, 5% were Black or African American, and 2% were Asian; 10% were Hispanic or Latino ethnicity.

At baseline, the type 1 diabetes mellitus population had diabetes mellitus for an average of 17 years and had a mean HbA1c of 8.3%, and the type 2 diabetes mellitus population had diabetes mellitus for an average of 11 years and had a mean HbA1c of 8.8%. At baseline, 33% of the population reported peripheral neuropathy, 32% reported retinopathy and 20% had a history of cardiovascular disease. Table 2 shows the frequency of common adverse reactions, excluding hypoglycemia, associated with the use of AFREZZA in the pool of controlled trials in adults with type 2 diabetes mellitus patients that occurred more commonly on AFREZZA than on placebo and/or comparator and occurred in at least 2% of patients treated with AFREZZA.

Table 2. Common Adverse Reactions That Occurred in ≥ 2% in Adult Patients with Type 2 Diabetes Mellitus (excluding Hypoglycemia) Treated with AFREZZA Adverse Reaction AFREZZA (n = 1,991) % Placebo a (n = 290) % Non-placebo comparators (n=1,363) % Cough 26 20 5 Throat pain or irritation 4 4 1 Headache 3 3 2 Diarrhea 3 1 2 Productive cough 2 1 1 Fatigue 2 1 1 Nausea 2 0.3 1 a Carrier particle without insulin was used as placebo [see Description ( 11.1 )]. Table 3 shows the frequency of common adverse reactions, excluding hypoglycemia, associated with the use of AFREZZA in the pool of active-controlled trials in adults with type 1 diabetes mellitus.

These adverse reactions occurred more commonly on AFREZZA than on comparator and occurred in at least 2% of patients treated with AFREZZA. Table 3. Common Adverse Reactions That Occurred in ≥ 2% in Adult Patients with Type 1 Diabetes Mellitus (excluding Hypoglycemia) Treated with AFREZZA Adverse Reaction AFREZZA (n=1,026)… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions ~2 min read ▾

2.5Dosage Modifications for Drug Interactions Dosage modification may be needed when: AFREZZA is used concomitantly with certain drugs that increase and/or decrease the glucose lowering effect [see Drug Interactions ( 7 )]. Switching from another insulin to AFREZZA [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.2 )]

7 DRUG INTERACTIONS Table 6 presents clinically significant drug interactions with AFREZZA. Table 6. Clinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs.

Mechanism and Clinical Effect(s) Concomitant use of these drugs with AFREZZA may increase the risk of hypoglycemia. Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs.

Mechanism and Clinical Effect(s) Concomitant use of these drugs with AFREZZA may reduce the blood glucose lowering effect of AFREZZA. Alcohol, Beta-blockers, Clonidine, and Lithium Salts Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. Mechanism and Clinical Effect(s) Concomitant use with AFREZZA may either increase or decrease the blood glucose lowering effect of AFREZZA.

Pentamidine Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. Mechanism and Clinical Effect(s) Concomitant use of pentamidine with AFREZZA may cause hypoglycemia, which may sometimes be followed by hyperglycemia Beta-blockers, Clonidine, Guanethidine, and Reserpine Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs.

Mechanism and Clinical Effect(s) Concomitant use of these drugs with AFREZZA may blunt the signs and symptoms of hypoglycemia, making it more difficult to recognize See full prescribing information for details regarding concomitant use of drugs that may ( 7 ): Decrease blood glucose lowering effect of AFREZZA Increase or decrease the blood glucose lowering effect of AFREZZA Blunt signs and symptoms of hypoglycemia

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary Limited available data with AFREZZA use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. Available information from published studies with human insulin use during pregnancy has not reported a clear association with human insulin and adverse developmental outcomes ( see Data ). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy ( see Clinical Considerations ).

In animal reproduction studies, there were no adverse developmental outcomes with subcutaneous administration of carrier particles (vehicle without insulin) to pregnant rats during organogenesis at doses 21 times the human daily dose of 99 mg AFREZZA, based on AUC (see Data ) . The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with HbA1c >7 and has been reported to be as high as 20-25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for DKA, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia- related morbidity.

Data Human Data There are limited data with AFREZZA use in pregnant women. Published data do not report a clear association with human insulin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when human insulin is used during pregnancy. However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and lack of blinding.

Animal Data In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 6 through 17 (organogenesis), no major malformations were observed at doses up to 100 mg/kg/day (21 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC). In pregnant rabbits given subcutaneous doses of 2, 10, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through 19 (organogenesis), adverse maternal effects were observed in all dose groups (at human systemic exposure following a daily dose of 99 mg AFREZZA, based on AUC).

In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through lactation day 20 (weaning), decreased epididymis and testes weights were observed in F1 male offspring, however, no decrease in fertility was noted, and impaired learning were observed in F1 pups at > 30 mg/kg/day (6 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).

8.2Lactation Risk Summary There are no data on the presence of AFREZZA in human milk, the effects on the breastfed infant, or the effects on milk production. One small published study reported that exogenous subcutaneous insulin was present in human milk. No adverse effects in infants were noted.

The carrier particles are present in rat milk ( see Data ). Potential adverse reactions that are related to inhalational administration of AFREZZA are unlikely to be associated with potential exposure of AFREZZA through breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AFREZZA and any potential adverse effects on the breastfed infant from AFREZZA or from the underlying maternal condition.

Data Subcutaneous administration of the carrier particle in lactating rats resulted in excre… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary Limited available data with AFREZZA use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. Available information from published studies with human insulin use during pregnancy has not reported a clear association with human insulin and adverse developmental outcomes ( see Data ). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy ( see Clinical Considerations ).

In animal reproduction studies, there were no adverse developmental outcomes with subcutaneous administration of carrier particles (vehicle without insulin) to pregnant rats during organogenesis at doses 21 times the human daily dose of 99 mg AFREZZA, based on AUC (see Data ) . The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with HbA1c >7 and has been reported to be as high as 20-25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for DKA, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia- related morbidity.

Data Human Data There are limited data with AFREZZA use in pregnant women. Published data do not report a clear association with human insulin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when human insulin is used during pregnancy. However, these studies cannot definitely establish the absence of any risk because of methodological limitations including small sample size and lack of blinding.

Animal Data In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 6 through 17 (organogenesis), no major malformations were observed at doses up to 100 mg/kg/day (21 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC). In pregnant rabbits given subcutaneous doses of 2, 10, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through 19 (organogenesis), adverse maternal effects were observed in all dose groups (at human systemic exposure following a daily dose of 99 mg AFREZZA, based on AUC).

In pregnant rats given subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier particles (vehicle without insulin) from gestation day 7 through lactation day 20 (weaning), decreased epididymis and testes weights were observed in F1 male offspring, however, no decrease in fertility was noted, and impaired learning were observed in F1 pups at > 30 mg/kg/day (6 times the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).

🧒 Pediatric Use 127 words ▾

8.4Pediatric Use The safety and effectiveness of AFREZZA to improve glycemic control have been established in pediatric patients 6 years of age and older with diabetes mellitus. Use of AFREZZA for this indication is supported by evidence from an adequate and well controlled trial in pediatric patients aged 6 years and older with type 1 or type 2 diabetes mellitus and from trials in adults with type 1 or type 2 diabetes mellitus [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.2 , 14.3 , 14.4 )] . The overall safety profile in pediatric patients was similar to adults [see Adverse Reactions ( 6.1 )] .

The safety and effectiveness of AFREZZA have not been established in pediatric patients less than 6 years of age.

🧓 Geriatric Use 139 words ▾

8.5Geriatric Use In the AFREZZA clinical studies , 671 (12%) patients were 65 years of age or older, of which 42 (0.8%) were 75 years of age or older. In these studies, 381 (13%) of AFREZZA-treated patients were 65 years of age or older, of which 20 (0.7%) were 75 years of age or older. No overall differences in effectiveness of AFREZZA have been observed between patients 65 years of age and older and younger adult patients [see Clinical Studies ( 14 )] .

Clinical studies of AFREZZA did not include sufficient numbers of patients 65 years of age and older to determine whether there were differences in safety between these patients and younger adult patients. Pharmacokinetic and pharmacodynamic studies to assess the effect of age on pharmacokinetics or pharmacodynamics on insulin human, respectively, have not been conducted.

🆘 Overdosage 121 words ▾

10 OVERDOSAGE Excess insulin administration may cause hypoglycemia and hypokalemia [see Warnings and Precautions ( 5.3 , 5.8 )] . Mild episodes of hypoglycemia due to insulin overdose can usually be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed.

Severe episodes of hypoglycemia (due to insulin overdose) with coma, seizure, or neurologic impairment may be treated with intramuscular or subcutaneous glucagon or concentrated intravenous glucose. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid recurrence of hypoglycemia. Hypokalemia should be corrected appropriately.

In the event of an overdose of AFREZZA, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

12.2Pharmacodynamics The time course of insulin action (i.e., glucose lowering) may vary considerably in different patients or within the same patient, or when switching from subcutaneous mealtime insulin to AFREZZA. The average pharmacodynamic profile [i.e., glucose lowering effect measured by glucose infusion rate (GIR) over time in a euglycemic clamp study] after administration of a single AFREZZA dose of 4, 12, and 48 units in 30 patients with type 1 diabetes mellitus is shown in Figure 2(A) , and key characteristics regarding the timing of the effects are described in Table 7 : Table 7.

Timing of Insulin Effect (i.e., mean pharmacodynamics effect) After Administration of a Single AFREZZA Dose in Patients (N=30) with Type 1 Diabetes Mellitus Parameter for Insulin Effect AFREZZA 4 units AFREZZA 12 units AFREZZA 48 units Time to first measurable effect ~12 minutes ~12 minutes ~12 minutes Time to peak effect ~35 minutes ~45 minutes ~55 minutes Time for effect to return to baseline ~90 minutes ~180 minutes ~270 minutes Figure 2. Results After Administration of AFREZZA 4, 12, and 48 Units in Patients with Type 1 Diabetes Mellitus (N=30) A) Mean Insulin Effect (Baseline-Corrected Glucose Infusion Rate); and B) Pharmacokinetic (Baseline-Corrected Serum Insulin Concentration Profiles) On average, the pharmacodynamics effect of AFREZZA, measured as area under the glucose infusion rate – time curve (AUC GIR) increased linearly with doses up to 48 units (106, 387, and 1581 mg/kg for 4, 12, and 48 units doses, respectively).

Intrapatient variability in AUC GIR and GIRmax was approximately 28% (95% CI 21-42%) and 27% (95% CI 20-40%), respectively. Figure 2

12.3Pharmacokinetics The area under the plasma concentration versus time curve (AUC) of insulin increased dose proportionally up to 48 units. Intrapatient variability of AUC and peak concentration (C max ) of insulin was approximately 16% (95% CI 12-23%) and 21% (95% CI 16-30%), respectively. Absorption The pharmacokinetic profiles for orally inhaled AFREZZA 4, 12, and 48 units from a study in 30 patients with type 1 diabetes mellitus are shown in Figure 2(B) .

A higher maximum plasma insulin concentration was achieved at an earlier timepoint in this study when patients were switched from subcutaneous mealtime insulin to AFREZZA [see Dosage and Administration ( 2.3 )]. The time to maximum serum insulin concentration (t max ) ranged from 10-20 minutes after oral inhalation of 4 to 48 units of AFREZZA. Elimination The apparent terminal half-life ranged from 120 to 206 minutes.

Serum insulin concentrations declined to baseline by approximately 60 to 240 minutes. Metabolism and Excretion The metabolism and excretion of AFREZZA are comparable to regular human insulin. Carrier Particles Clinical pharmacology studies showed that carrier particles [see Description ( 11.1 )] are not metabolized and are eliminated unchanged in the urine following the lung absorption.

Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed. The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces. Specific Populations Pediatric Patients In pediatric patients aged 8 years and older, insulin serum concentration profiles (T max and time decline to baseline) showed a similar time course between adult and pediatric patients following administration of AFREZZA.

Insulin Cmax and AUC increased in a dose-dependent manner following a single dose of 4 units to 12 units. Drug Interaction Studies Bronchodilators and Inhaled Steroids Albutero… [Excerpted — this section continues on DailyMed.]

🧬 Mechanism of Action 42 words ▾

12.1Mechanism of Action Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

📦 How Supplied / Storage and Handling ~2 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING AFREZZA (insulin human) Inhalation Powder is available as 4 unit, 8 unit and 12 unit single-use cartridges. Three cartridges are contained in a single cavity of a blister strip. Each card contains 5 blister strips (each containing three cartridges) separated by perforations for a total of 15 cartridges.

Two cards of the same cartridge strength are packaged in a foil laminate overwrap (30 cartridges per foil package). The cartridges are color-coded, blue for 4 units, green for 8 units and yellow for 12 units. Each cartridge is marked with “afrezza” and “4 units”, “8 units” or “12 units”.

The AFREZZA Inhaler is individually packaged in a clear overwrap. The inhaler is fully assembled with a removable mouthpiece cover. The AFREZZA Inhaler can be used for up to 15 days from the date of first use.

After 15 days of use, the inhaler must be discarded and replaced with a new inhaler. AFREZZA (insulin human) Inhalation Powder is available in the following configurations: NDC Cartridge Strength Quantity of Cartridges per Strength Total Quantity of Cartridges per Kit Total Units in Kit Number of Inhalers 47918-874-90 4 units 90 90 360 Units 2 47918-878-90 8 units 90 90 720 Units 2 47918-891-90 12 units 90 90 1,080 Units 2 47918-898-18 8 units, 12 units 90 180 1,800 Units 2 47918-880-18 (Titration Pack) 4 units, 8 units 90 180 1,080 Units 2 47918-902-18 (Titration Pack) 4 units, 8 units, 12 units 60 180 1,440 Units 2 Storage : Not in Use: Refrigerated Storage 2ºC to 8ºC (36ºF to 46ºF) * If a foil package, blister card or strip is not refrigerated, the contents must be used within 10 days.

Sealed (Unopened) Foil Package May be stored until the Expiration Date* Sealed (Unopened) Blister Cards and Strips Must be used within 1 month* In Use: Room Temperature Storage 25ºC (77ºF), excursions permitted 15ºC to 30ºC (59ºF to 86ºF) Sealed (Unopened) Blister Cards and Strips Must be used within 10 days Opened Strips Must be used within 3 days Do not put a blister card or strip back into the refrigerator after being stored at room temperature. Inhaler Storage : Store refrigerated or at room temperature 2ºC to 25ºC (36ºF to 77ºF); excursions permitted.

Inhaler may be stored refrigerated, but should be at room temperature before use. Handling : Before use, cartridges should be at room temperature for 10 minutes.

📋 Description 165 words ▾

11 DESCRIPTION

11.1AFREZZA Cartridges Human insulin is a rapid acting human insulin produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12). Chemically, human insulin has the empirical formula C 257 H 383 N 65 O 77 S 6 and a molecular weight of 5808. Human insulin has the following primary amino acid sequence: AFREZZA (human insulin) inhalation powder is available in single-use plastic cartridges filled with a white powder containing insulin (human), which is administered via oral inhalation using the AFREZZA Inhaler only.

Insulin is adsorbed onto carrier particles consisting of fumaryl diketopiperazine (FDKP) and polysorbate 80. AFREZZA Inhalation Powder is a dry powder supplied as 4 unit, 8 unit or 12 unit cartridges. Primary Amino Acid Sequence

11.2AFREZZA Inhaler The AFREZZA Inhaler is breath-powered by the patient. When the patient inhales through the device, the powder is aerosolized and delivered to the lung. The amount of AFREZZA delivered to the lung will depend on individual patient factors.

💬 Information for Patients ~2 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide and Instructions for Use ). Instruct patients to use AFREZZA only with the AFREZZA inhaler. Acute Bronchospasm in Patients with Chronic Lung Disease Advise patients that if they experience any respiratory difficulty after inhalation of AFREZZA, they should report it to their healthcare provider immediately for assessment [see Warnings and Precautions ( 5.1 )] .

Hypoglycemia Instruct patients on self-management procedures including glucose monitoring, proper inhalation technique, and management of hypoglycemia and hyperglycemia, especially at initiation of AFREZZA therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, or skipped meals [see Warnings and Precautions ( 5.3 )] .

Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery. Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision [see Warnings and Precautions ( 5.2 )].

Decline in Pulmonary Function Inform patients that AFREZZA can cause a decline in lung function [see Warnings and Precautions ( 5.4 )]. Lung Cancer Inform patients to promptly report any signs or symptoms potentially related to lung cancer [see Warnings and Precautions ( 5.5 )]. Diabetic Ketoacidosis Instruct patients to carefully monitor their blood glucose during illness, infection, and other risk situations for DKA and to contact their healthcare provider if their blood glucose control worsens [see Warnings and Precautions ( 5.6 )].

Hypersensitivity Reactions Advise patients that hypersensitivity reactions can occur with insulin therapy including AFREZZA. Inform patients on the symptoms of hypersensitivity reactions [see Warnings and Precautions ( 5.7 )]. Manufactured by: MannKind Corporation, Danbury, CT 06810 US License No. #2190 © 2016 – 2026 MannKind Corporation AFREZZA is a registered trademark of MannKind Corporation Patent: www.mannkindcorp.com/patent-notices

💬 Medication Guide ~3 min read ▾

MEDICATION GUIDE AFREZZA ® (uh-FREZZ-uh) (insulin human) inhalation powder, for oral inhalation use What is the most important information I should know about AFREZZA? AFREZZA can cause serious side effects, including: Sudden lung problems (bronchospasms). Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD).

Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working. What is AFREZZA? AFREZZA is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults and children 6 years of age and older, with diabetes mellitus.

AFREZZA is not for use to treat diabetic ketoacidosis. AFREZZA must be used with basal insulin in people who have type 1 diabetes mellitus. It is not known if AFREZZA is safe and effective for use in people who smoke.

AFREZZA is not for use in people who smoke or have recently stopped smoking (less than 6 months). It is not known if AFREZZA is safe and effective in children under 6 years of age. Who should not use AFREZZA?

Do not use AFREZZA if you: Are having an episode of low blood sugar (hypoglycemia). Have chronic lung problems such as asthma or COPD. Are allergic to regular human insulin or any of the ingredients in AFREZZA.

See the end of this Medication Guide for a complete list of ingredients in AFREZZA. What should I tell my healthcare provider before using AFREZZA? Before using AFREZZA, tell your healthcare provider about all your medical conditions, including if you: Have lung problems such as asthma or COPD.

Have or have had lung cancer. Are using any inhaled medications. Smoke or have recently stopped smoking.

Have kidney or liver problems. Are pregnant, planning to become pregnant, or are breastfeeding. AFREZZA may harm your unborn or breastfeeding baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements. Before you start using AFREZZA, talk to your healthcare provider about low blood sugar and how to manage it. How should I use AFREZZA?

Read the detailed Instructions for Use that comes with your AFREZZA. Take AFREZZA exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much AFREZZA to use and when to use it.

Your healthcare provider will train you or your caregiver in how to use AFREZZA. After training, you or your child (10 years of age or older) may self-administer AFREZZA. Know the strength of AFREZZA you use.

Do not change the amount of AFREZZA you use unless your healthcare provider tells you to. Take AFREZZA at the beginning of your meal. Check your blood sugar levels.

Ask your healthcare provider what your blood sugar should be and when you should check your blood sugar levels. Keep AFREZZA and all medicines out of the reach of children. Your dose of AFREZZA may need to change because of: Change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.

What should I avoid while using AFREZZA? While using AFREZZA do not: Drive or operate heavy machinery, until you know how AFREZZA affects you. Drink alcohol or use over-the-counter medicines that contain alcohol.

Smoke. What are the possible side effects of AFREZZA? AFREZZA may cause serious side effects that can lead to death, including: See “What is the most important information I should know about AFREZZA?” Low blood sugar (hypoglycemia).

Signs and symptoms that may indicate low blood sugar include: Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger. Decreased lung function. Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it and yearly a… [Excerpted — this section continues on DailyMed.]

🧬 Pharmacokinetics ~2 min read ▾

12.3Pharmacokinetics The area under the plasma concentration versus time curve (AUC) of insulin increased dose proportionally up to 48 units. Intrapatient variability of AUC and peak concentration (C max ) of insulin was approximately 16% (95% CI 12-23%) and 21% (95% CI 16-30%), respectively. Absorption The pharmacokinetic profiles for orally inhaled AFREZZA 4, 12, and 48 units from a study in 30 patients with type 1 diabetes mellitus are shown in Figure 2(B) .

A higher maximum plasma insulin concentration was achieved at an earlier timepoint in this study when patients were switched from subcutaneous mealtime insulin to AFREZZA [see Dosage and Administration ( 2.3 )]. The time to maximum serum insulin concentration (t max ) ranged from 10-20 minutes after oral inhalation of 4 to 48 units of AFREZZA. Elimination The apparent terminal half-life ranged from 120 to 206 minutes.

Serum insulin concentrations declined to baseline by approximately 60 to 240 minutes. Metabolism and Excretion The metabolism and excretion of AFREZZA are comparable to regular human insulin. Carrier Particles Clinical pharmacology studies showed that carrier particles [see Description ( 11.1 )] are not metabolized and are eliminated unchanged in the urine following the lung absorption.

Following oral inhalation of AFREZZA, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed. The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces. Specific Populations Pediatric Patients In pediatric patients aged 8 years and older, insulin serum concentration profiles (T max and time decline to baseline) showed a similar time course between adult and pediatric patients following administration of AFREZZA.

Insulin Cmax and AUC increased in a dose-dependent manner following a single dose of 4 units to 12 units. Drug Interaction Studies Bronchodilators and Inhaled Steroids Albuterol increased the AUC insulin after AFREZZA administration by 25% in patients with asthma [see Drug Interactions ( 7 ) ]. AFREZZA is contraindicated in patients with asthma.

In a study in healthy volunteers no significant change in insulin exposure was observed when fluticasone was administered following AFREZZA administration.

🧬 Pharmacodynamics ~1 min read ▾

12.2Pharmacodynamics The time course of insulin action (i.e., glucose lowering) may vary considerably in different patients or within the same patient, or when switching from subcutaneous mealtime insulin to AFREZZA. The average pharmacodynamic profile [i.e., glucose lowering effect measured by glucose infusion rate (GIR) over time in a euglycemic clamp study] after administration of a single AFREZZA dose of 4, 12, and 48 units in 30 patients with type 1 diabetes mellitus is shown in Figure 2(A) , and key characteristics regarding the timing of the effects are described in Table 7 : Table 7.

Timing of Insulin Effect (i.e., mean pharmacodynamics effect) After Administration of a Single AFREZZA Dose in Patients (N=30) with Type 1 Diabetes Mellitus Parameter for Insulin Effect AFREZZA 4 units AFREZZA 12 units AFREZZA 48 units Time to first measurable effect ~12 minutes ~12 minutes ~12 minutes Time to peak effect ~35 minutes ~45 minutes ~55 minutes Time for effect to return to baseline ~90 minutes ~180 minutes ~270 minutes Figure 2. Results After Administration of AFREZZA 4, 12, and 48 Units in Patients with Type 1 Diabetes Mellitus (N=30) A) Mean Insulin Effect (Baseline-Corrected Glucose Infusion Rate); and B) Pharmacokinetic (Baseline-Corrected Serum Insulin Concentration Profiles) On average, the pharmacodynamics effect of AFREZZA, measured as area under the glucose infusion rate – time curve (AUC GIR) increased linearly with doses up to 48 units (106, 387, and 1581 mg/kg for 4, 12, and 48 units doses, respectively).

Intrapatient variability in AUC GIR and GIRmax was approximately 28% (95% CI 21-42%) and 27% (95% CI 20-40%), respectively. Figure 2

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES

14.1Overview of Clinical Studies of AFREZZA Adult and Pediatric Patients 6 Years of Age and Older with Diabetes Mellitus AFREZZA has been studied in adults with type 1 diabetes mellitus in combination with basal insulin. The efficacy of AFREZZA, in combination with basal insulin, in adult patients with type 1 diabetes mellitus was compared to insulin aspart in combination with basal insulin. AFREZZA has been studied in adults with type 2 diabetes in combination with oral antidiabetic drugs.

The efficacy of AFREZZA in type 2 diabetes patients was compared to placebo inhalation. AFREZZA has been studied in pediatric patients aged 6 to 17 years with type 1 and type 2 diabetes mellitus in combination with basal insulin. The efficacy of AFREZZA, in combination with basal insulin was compared to rapid-acting insulin analogs (RAA) in combination with basal insulin.

14.2Adults with Type 1 Diabetes Mellitus Patients with inadequately controlled type 1 diabetes mellitus participated in a 24-week, open-label, active-controlled study (NCT01445951) to evaluate the glucose lowering effect of mealtime AFREZZA used in combination with a basal insulin. Following a 4-week basal insulin optimization period, 344 patients were randomized to AFREZZA by oral inhalation (n=174) or insulin aspart given subcutaneously (n=170) at each meal of the day. All patients received basal insulin.

Mealtime insulin doses were titrated to glycemic goals for the first 12 weeks and kept stable for the last 12 weeks of the study. The trial population had the following characteristics: mean age was 38, 56% were female, 96% were White, 3% were Black or African American, less than 1% were Asian, less than 1% were Native Hawaiian or Pacific Islander, less than 1% were other races, and 10% were Hispanic or Latino ethnicity. Results At Week 24, treatment with mealtime AFREZZA and basal insulin provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin of 0.4%.

AFREZZA and basal insulin provided less HbA1c reduction than insulin aspart and basal insulin, and the difference was statistically significant. More patients in the insulin aspart and basal insulin group achieved the HbA1c target of ≤7% ( Table 8 ). Table 8.

Results at Week 24 in an Active-Controlled Study of Mealtime AFREZZA plus Basal Insulin in Adults with Type 1 Diabetes Mellitus Efficacy Parameter AFREZZA + Basal Insulin (N=174) Insulin Aspart + Basal Insulin (N=170) HbA1c (%) Baseline (adjusted mean a ) 7.94

7.92Change from baseline (adjusted mean a,b ) -0.21 -0.40 Difference from insulin aspart (adjusted mean a,b ) (95% CI) 0.19 (0.02, 0.36) Percentage of patients achieving HbA1c ≤ 7% c 14% 27% Fasting Plasma Glucose (mg/dL) Baseline (adjusted mean a ) 153.9 151.6 Change from baseline (adjusted mean a, b ) -25.3

10.2Difference from insulin aspart (adjusted mean a,b ) (95% CI) -35.4 (-56.3, -14.6) a Adjusted mean was obtained using a Mixed Model Repeated Measures (MMRM) approach with HbA1c or FPG as the dependent variable and treatment, visit, region, basal insulin stratum, and treatment by visit interaction as fixed factors, and corresponding baseline as a covariate. An autoregression (1) [AR(1)] covariance structure was used. b Data at 24 weeks were available from 131 (75%) and 150 (88%) patients randomized to the AFREZZA and insulin aspart groups, respectively. c The percentage was calculated based on the number of patients randomized to the trial.

14.3Adults with Type 2 Diabetes Mellitus A total of 479 adult patients with type 2 diabetes mellitus inadequately controlled on optimal/maximally tolerated doses of metformin only, or 2 or more oral antidiabetic (OAD) agents participated in a 24-week, double-blind, placebo-controlled study (NCT01451398). Following a 6-week run-in period, 353 patients were randomized to AFREZZA by oral inhalation (n=177) or an inhaled placebo powder without insulin (n=176). Insulin doses were titrated for the first 12 weeks and kep… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology ~1 min read ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis In a 104 week carcinogenicity study, rats were given doses up to 46 mg/kg/day of the carrier and up to 1.23 mg/kg/day of insulin, by nose-only inhalation. No increased incidence of tumors was observed at systemic exposures equivalent to the insulin at a daily AFREZZA dose of 99 mg, based on a comparison of relative body surface areas across species.

13.2Mutagenesis No increased incidence of tumors was observed in a 26 week carcinogenicity study in transgenic mice (Tg-ras-H2) given doses up to 75 mg/kg/day of carrier and up to 5 mg/kg/day of AFREZZA. AFREZZA was not genotoxic in Ames bacterial mutagenicity assay and in the chromosome aberration assay, using human peripheral lymphocytes with or without metabolic activation. The carrier alone was not genotoxic in the in vivo mouse micronucleus assay.

13.3Impairment of Fertility In fertility study in male and female rats at subcutaneous doses of 10, 30, and 100 mg/kg/day of carrier (vehicle without insulin), there were no adverse effects on male fertility at doses up to 100 mg/kg/day. In female rats dosed 2 weeks prior to mating until gestation day 7, there was increased pre- and post-implantation loss at 100 mg/kg/day but not at 30 mg/kg/day (21 times and 6 times, respectively the human systemic exposure at a daily dose of 99 mg AFREZZA, based on AUC).

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 62 words ▾

13.1Carcinogenesis In a 104 week carcinogenicity study, rats were given doses up to 46 mg/kg/day of the carrier and up to 1.23 mg/kg/day of insulin, by nose-only inhalation. No increased incidence of tumors was observed at systemic exposures equivalent to the insulin at a daily AFREZZA dose of 99 mg, based on a comparison of relative body surface areas across species.

📖 Instructions for Use ~3 min read ▾

INSTRUCTIONS FOR USE AFREZZA ® (uh-FREZZ-uh) (insulin human) inhalation powder, for oral inhalation use This Instructions for Use contains information on how to use AFREZZA ® (insulin human) inhalation powder dry powder inhaler. Read this Instructions for Use all the way through before you start using AFREZZA and each time you get a new AFREZZA Inhaler. There may be new information.

This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Your healthcare provider should show you or your child (10 years of age or older) how to use the AFREZZA Inhaler the right way before it is used for the first time. Contact your healthcare provider if you have any questions.

Important Information You Need to Know Before Inhaling AFREZZA: AFREZZA starts acting fast, so take your medicine right before you eat a meal. For oral inhalation only. AFREZZA is a mealtime (short acting) insulin.

Contact your healthcare provider before switching insulins. Do not put cartridges in your mouth. Do not swallow cartridges.

Do not use AFREZZA cartridges if they are expired. Only use AFREZZA cartridges with the AFREZZA Inhaler. Do not breathe in the AFREZZA powder any other way.

Do not open the cartridges. The inhaler opens the cartridge automatically during use. Do not reuse cartridges.

Cartridges are single use and should only be used 1 time. You can tell a cartridge has been used when the cartridge cup has moved from the front to the middle position in the cartridge base. If your prescribed AFREZZA dose is higher than 12 units, you will need to use more than 1 cartridge.

If using more than 1 cartridge for a dose, the cartridges can be used in any order, regardless of cartridge strength. Do not insert more than 1 cartridge into the inhaler at a time. Always remove the used cartridge from the inhaler before inserting a new one.

Only use 1 inhaler at a time. The same inhaler should be used for the 4 unit, 8 unit or 12 unit cartridges. The same inhaler should be used even when needing to use more than 1 cartridge for your dose.

Do not share the AFREZZA Inhaler with anyone else. The inhaler lasts for 15 days. After 15 days of use, throw away your used inhaler and get a new one.

Warning: After a cartridge is loaded into the inhaler, keep the inhaler level until the inhaler mouthpiece is in your mouth to avoid spilling the AFREZZA powder. Do not flip or rotate inhaler. If any AFREZZA powder spills, throw away the cartridge into regular household trash, and wash your hands.

Then restart the procedure with a new cartridge. AFREZZA Inhaler Parts (Figure A): AFREZZA Cartridge Parts and Strengths (Figure B): Storage Information (Figure C) Additional Storage Information Important: Before use, cartridges and inhaler should be left out at room temperature for at least 10 minutes. Do not put blister cards or blister strips back into the refrigerator after being opened or stored at room temperature.

Keep AFREZZA and all medicines out of reach of children. Do not let cartridge or inhaler get wet. Do not leave or store cartridges in the inhaler.

Use 1 inhaler at a time. The same inhaler should be used to take 4 unit, 8 unit or 12 unit cartridges. Always store the inhaler with the mouthpiece cover on.

Preparing to Inhale AFREZZA Step 1: Choose cartridges for dose

1.1Figure out what AFREZZA cartridges are needed for your dose. Use the dosage chart below (Figure D) to determine the number of AFREZZA cartridges you can use for your dose. Note: If your prescribed AFREZZA dose is higher than 12 units, you will need to use more than 1 cartridge. If using more than 1 cartridge for a dose, the cartridges can be used in any order, regardless of cartridge strength. Step 2: Get and check blister strip(s)

2.1Open Foil package and remove blister card(s) needed for your dose (Figure E).

2.2Get the blister strip(s) with the cartridges you need for your dose If needed, tear blister strip from the blister card (Figure F)… [Excerpted — this section continues on DailyMed.]

📄 Recent Major Changes 27 words ▾

Indications and Usage ( 1 ) 5/2026 Dosage and Administration Important Administration Information ( 2.2 ) 5/2026 Recommended Starting Mealtime Dosage of AFREZZA ( 2.3 ) 1/2026

📄 Package Label / Principal Display Panel ~2 min read ▾

Principal Display Panel 90 − 4 unit cartridges and 2 inhalers NDC 47918-874-90 Rx ONLY afrezza® (insulin human) Inhalation Powder 4 units per cartridge 90 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 90 – 4 unit cartridges + 2 inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 90 − 4 unit cartridges and 2 inhalers

Principal Display Panel 90 – 8 unit cartridges and 2 inhalers NDC 47918-878-90 Rx ONLY afrezza® (insulin human) Inhalation Powder 8 units per cartridge 90 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 90 – 8 unit cartridges + 2 inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 90 – 8 unit cartridges and 2 inhalers

Principal Display Panel 90 – 12 unit cartridges and 2 inhalers NDC 47918-891-90 Rx ONLY afrezza® (insulin human) Inhalation Powder 12 units per cartridge 90 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 90 – 12 unit cartridges + 2 inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 90 – 12 unit cartridges and 2 inhalers

Principal Display Panel 180 cartridges; 60 – 4 unit cartridges, 60 – 8 unit cartridges and 60 – 12 unit cartridges and 2 inhalers (Titration Pack) NDC 47918-902-18 Rx ONLY afrezza® (insulin human) Inhalation Powder 4 units per cartridge 8 units per cartridge 12 units per cartridge 180 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 60 – 4 unit cartridges 60 – 8 unit cartridges 60 – 12 unit cartridges 2 - inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 180 cartridges; 60 – 4 unit cartridges, 60 – 8 unit cartridges and 60 – 12 unit cartridges and 2 inhalers (Titration Pack)

Principal Display Panel 180 cartridges; 90 – 4 unit cartridges and 90 – 8 unit cartridges and 2 inhalers (Titration Pack) NDC 47918-880-18 Rx ONLY afrezza® (insulin human) Inhalation Powder 4 units per cartridge 8 units per cartridge titration pack 180 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 90 – 4 unit cartridges 90 – 8 unit cartridges 2 - inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 180 cartridges; 90 – 4 unit cartridges and 90 – 8 unit cartridges and 2 inhalers (Titration Pack)

Principal Display Panel 180 cartridges; 90 – 8 unit cartridges and 90 – 12 unit cartridges and 2 inhalers NDC 47918-898-18 Rx ONLY afrezza® (insulin human) Inhalation Powder 8 units per cartridge 12 units per cartridge 180 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 90 – 8 unit cartridges 90 – 12 unit cartridges 2 - inhalers Dispense the enclosed Medication Guide to each patient mannkind® Principal Display Panel 180 cartridges; 90 – 8 unit cartridges and 90 – 12 unit cartridges and 2 inhalers

Principal Display Panel 30 cartridges;15 – 4 unit cartridges and 15 – 8 unit cartridges (Sample Kit) NDC 47918-904-30 Rx ONLY afrezza® (insulin human) Inhalation Powder 4 units per cartridge 8 units per cartridge 30 single-use cartridges FOR ORAL INHALATION ONLY Carton Contains: 15 – 4 unit cartridges 15 – 8 unit cartridges 1 - inhaler Dispense the enclosed Medication Guide to each patient mannkind® afr01-0008-39

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Afrezza — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Afrezza. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$7.66M
Claims incl. refills
4K
Beneficiaries
2.1K
Spend / beneficiary
$3,648.45
Spend / claim
$1,936.74
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for AFREZZA (this brand).

Top reported reactions

Blood Glucose Increased1,327
Hypoglycaemia459
Cough446
Blood Glucose Decreased398
Dyspnoea398
Hyperglycaemia357
Diarrhoea341

Age at onset

Neonate60
Infant4
Child6
Adolescent15
Adult1,152
Elderly766

Reporter sex

8,027 reports
Male · 48%
Female · 51%
Unknown · 0%

Serious outcomes

Hospitalization3,161
Death790
Life-threatening600
Disabling285
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 791 400
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Kit / multi-component package

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Mannkind Corporation. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Mannkind Corporation is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.